AQUEOUS PHARMACEUTICAL FORMULATIONS OF ERYTHROPOIETIN AND THE USE THEREOF

摘要

Aqueous pharmaceutical formulations of proteins with erythropoietin activity, especially of human native and of recombinant human erythropoietin (EPO) are described. Highly purified EPO without foreign proteins or other customary stabilizers retains at least about 78% of its original activity for at least 1 year at room temperature in a physiologically tolerated aqueous phosphate buffer which contains a physiologically tolerated alkali metal halide but otherwise no stabilizing additives and has a pH of 6 to 8. The products in this aqueous pharmaceutical formulation are particularly suitable for subcutaneous or intramuscular administration.